Sorrento Therapeutics Inc (SRNE): Glad FDA acted quickly on COVISHIELD!...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	57
Posts	5700
Boards Moderated	0
Alias Born	12/13/2004

dia76ca

Re: None

Monday, 03/14/2022 10:45:42 AM

Monday, March 14, 2022 10:45:42 AM

Glad FDA acted quickly on COVISHIELD!

Sorrento Announces FDA Authorization to Proceed With Phase 1 Study Of Intranasal STI-9199 (COVISHIELD), a Potent Neutralization Antibody Against Covid-19 Viruses
March 2, 2022 at 11:24 AM EST

FDA granted IND clearance today for STI-9199 (COVISHIELD™) for a Phase 1 safety and pharmacokinetic study in healthy volunteers.
Initial trials are expected to be followed by a multinational Phase 2/3 trial in both mild and moderate COVID-19 patients.
STI-9199 has demonstrated in vitro and in vivo activity against all SARS-CoV-2 variants tested, including the Omicron strain BA.1, Omicron BA.1+R346K and Omicron BA.2.

"The refusal of the real is the number one dogma of our time" Rene Girard

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent SRNE News

Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:31:06 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:15:31 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 01:51:06 AM
Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 09:25:07 PM
Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/07/2023 08:15:35 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 10:01:54 AM
Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 10:26:26 AM